Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs).

Abstract: A method is provided comprising: generating a snapshot of a volume in a storage system; generating a snapshot marker and adding the snapshot marker to a transaction log of the storage system; scanning the transaction log to identify one or more records that have been added to the transaction log before the snapshot marker, and marking each of the identified records as a splitflush record; flushing any record that is stored in the transaction log by: (a) detecting whether the record is marked as a splitflush record, (b) when the record is marked as a splitflush record, copying the record both to a data store and to the snapshot, and (c) when the record is not marked as a splitflush record, copying the record to the data store only.

Abstract: The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin.

Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin.

Abstract: The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs).

Abstract: The invention provides compositions that increase the mobilization, homing, expansion, and/or differentiation of stem cells and methods of using the same for the treatment of mammals.

Abstract: The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical product comprising a DA-DKP containing composition.

Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The invention provides a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) comprising administering to an animal in need thereof, an effective amount a pharmaceutical composition containing N-acetyl-kynurenine (NAK) or pharmaceutically acceptable salts thereof as the active ingredient.

Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification. The invention further provides a kit. The kit comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.

Abstract: Methods and apparatus for supporting multiple emergency users in a push-to-talk group. The methods include receiving a first emergency alert from a first user device in the push-to-talk group; receiving a second emergency alert from a second user device in the push-to-talk group; causing the first emergency alert and second emergency alert to be provided to each of the console devices in the push-to-talk group; receiving, from the first user device, a first communication and receiving, from the second user device, a second communication; causing the first communication and the second communication to each of the console devices in the push-to-talk group. The methods further include receiving, from a first console device, a selection of one of the first user device and the first emergency alert; and, in response subsequently selectively routing a third communication from the first user device to the first console device and not to a second console device in the push-to-talk group.

Abstract: A method is provided comprising: generating a snapshot of a volume in a storage system; generating a snapshot marker and adding the snapshot marker to a transaction log of the storage system; scanning the transaction log to identify one or more records that have been added to the transaction log before the snapshot marker, and marking each of the identified records as a splitflush record; flushing any record that is stored in the transaction log by: (a) detecting whether the record is marked as a splitflush record, (b) when the record is marked as a splitflush record, copying the record both to a data store and to the snapshot, and (c) when the record is not marked as a splitflush record, copying the record to the data store only.

Abstract: The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical product comprising a DA-DKP containing composition.

Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

Abstract: Methods and systems for managing a radio communication group call. One system includes a server configured to be communicatively coupled to a first communication device, a second communication device and a third communication device. The server includes an electronic processor configured to establish a half-duplex group call between the first communication device, the second communication device, and the third communication device. The processor receives, from the second communication device, an audio signal and receives, from the first communication device, a soft preemption talk request. The electronic processor establishes, in response to receiving the soft preemption talk request, a full-duplex private call between the first communication device and the second communication device and transmits audio of the full-duplex private call to the third communication device.